STOCKS TELEGRAPH

Tag: TCOM

  • Trip.com Group Ltd. (TCOM) stock Bullish Premarket on Fiscal 2021 Results

    Trip.com Group Ltd. (TCOM) stock Bullish Premarket on Fiscal 2021 Results

    On March 24, Trip.com Group Ltd. (TCOM) had advanced by 8.24% in the premarket, at the last check. This bullishness comes from the company’s latest earnings report for Q4 and fiscal 2021, released on March 23, 2022.

    Source: Investopedia

    In the previous trading session on Wednesday, the stock traded in the red on confusion over the earnings among the investors. Hence, it seems investors were not sure of the company’s upcoming earnings, and thus the stock declined by 0.66% during the session. TCOM closed the session at a price of $24.02 per share while the volume of shares exchanged was above the average at 7.75 million. Following the results announcement, the stock was trading at a value of $26.00 in the premarket today, at the time of writing.

    The travel-related services provider, Trip.com Group Ltd. is based in Shanghai, China. Currently, the company’s 637.46 million outstanding shares trade at a market capitalization of $15.19 billion.

    TCOM’s 2021 Financial Results

    Net Revenue

    The company reported net revenue of RMB4.7 billion (US$735 million) for Q4 and RMB20.0 billion (US$3.1 billion) for fiscal 2021. The net revenue for Q4 2021 declined by 6% YOY while the full-year revenue increased by 9% YOY.

    Net loss/Income

    Moreover, TCOM had a net loss of RMB834 million (US$131 million) in Q4 2021, against RMB1.0 billion in the year-ago period. The non-GAAP net income was RMb309 million in Q4 2021.

    Additionally, the net loss and non-GAAP net income in fiscal 2021 were RMB550 million (US$86 million) and RMB1.4 billion (US$213 million) respectively.

    EPS/Loss Per Share

    Resultantly, the diluted loss per share and per ADS was RMB1.29 (US$0.20) for Q4 and RMB0.87 (US$0.14) for fiscal 2021.

    Adjusted EBITDA

    Furthermore, the adjusted EBITDA was RMB54 million (US$7 million) in Q4 2021, while it was RMB1.3 billion (US$203 million) for the full year.

    Cash Balance

    At the end of fiscal 2021, the company’s cash, cash equivalents, restricted cash, short-term investments, etc. totaled RMB63.9 billion (US$10.0 billion).

    TCOM’s AGM Results

    On December 21, 2021, the company announced the results of its Annual General Meeting in which both the special resolutions were duly adopted. The two special resolutions were: i) Adoption of the company’s Chinese name as the dual foreign name of the company, and ii) deletion of the Second Amended and Restated Memorandum of Association and Articles of Association upon its substitution by the Third Amended and Restated MoA and AoA.

  • Diffusion Pharmaceuticals, Inc. (DFFN) Stock Undergoes Minor Volatility Ahead of TCOM Trial Findings

    Diffusion Pharmaceuticals, Inc. (DFFN) Stock Undergoes Minor Volatility Ahead of TCOM Trial Findings

    Diffusion Pharmaceuticals, Inc. (DFFN) stock prices were down by 3.33% as of the market closing on June 29th, 2021, bringing the price per share down to USD$0.7557 at the end of the trading day. Subsequent pre-market fluctuations saw the stock surge by 5.99%%, bringing it up to USD$0.801.

    Phase 1 Trial

    The company announced topline results from its Phase 1 trial of trans sodium crocetinate (TSC), its lead product candidate, on June 30th, 2021. Transcutaneous oxygen monitoring (TCOM) was used to measure the direct pharmacodynamic effects of TSC on peripheral tissue oxygenation in healthy normal volunteers enrolled for the trial. Topline results were founded on analyses of the primary endpoint data, indicating a positive dose-response trend in TCOM readings after TSC administration during the measurement period, as compared to a placebo.

    Trial Results

    Statistical significance was not reached in the magnitude of the treatment’s effect, largely because of the small number of healthy subjects in each cohort, as well as the inherent variability of tcp02 measurement. Despite this, primary endpoint data trends indicated improved peripheral oxygenation as compared to the placebo, with no evidence of hyperoxygenation. TSC was found to be safe and well-tolerated at all doses tested in the trial, with no major adverse events or dose-limiting toxicities.

    Scope of TSC Data

    The data collected served to further elucidate TSC’s exposure-response relationship, which the company will use to build on their clinical development strategy. Upcoming study designs for future trials will be informed by the collected data, as will the ongoing investigation of the timing of administration to maximize clinical efficacy. DFFN believes the data will complement findings from the company’s Covid-19 trial, as well as supporting the ongoing execution of its three well-controlled Oxygenation Trials.

    Supporting TSC Trials

    Each trial is uniquely designed to differentially explore TSC’s unique mechanism of action, with the individual and collective data from these studies forecasted to inform the company’s late phase programs and clinical indications in the push for the commercialization of TSC. The first of the trials was the TCOM Trial, with the primary endpoint evaluating the relative change in TCOM readings from baseline after TSC administration as compared to the placebo.

    Future Outlook for DFFN

    Armed with the recent results of their most recent clinical trial, DFFN is poised to capitalize on the opportunities afforded to it by the expanded scope of options made available to it. Investors are confident that the company will continue to ensure a continued trajectory of success by making use of the resources at their disposal and trial findings as they arise.